Gold-Rally ohne Ende?
Diese 1-Mio.-Unzen-Story in Westafrika könnte der nächste Hebel auf den Boom sein
Anzeige
Original-Research

Cantourage Group SE (von NuWays AG): BUY 20.01.2026, 09:00 Uhr von EQS Research Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Cantourage Group 3,235 EUR -7,17 % Lang & Schwarz

Original-Research: Cantourage Group SE - from NuWays AG

20.01.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to Cantourage Group SE

Company Name: Cantourage Group SE
ISIN: DE000A3DSV01
 
Reason for the research: Update
Recommendation: BUY
Target price: EUR 10
Target price on sight of: 12 months
Last rating change:
Analyst: Christian Sandherr

FY26 outlook: Continued growth despite temporary headwinds

German market dynamics remain challenging, yet manageable. Germany is in the midst of changing its current cannabis laws. The most likely outcome would require a physical doctor’s visit in order to receive a prescription. As large numbers of patients would have to re-qualify their current prescriptions, it is expected that this would lead to a temporary demand shock as well as a certain “wash-out” of less active patients. Germany is also considering restricting online pharmacies from dispensing medical cannabis.

In our view, Cantourage is well positioned to weather potential regulatory changes. For one, the company is already adapting its product mix toward higher-margin premium strains which are typically less exposed to demand shocks. Cantourage is also strengthening its cooperations with offline pharmacies and adapting its telemedicine platform’s, telecan, operational set-up (i.e. connecting patients with physical doctors).

UK and Poland to show strong growth. Next to Germany, the UK and Poland are Cantourage’s most important end markets. As both markets are seen to remain on a strong growth path (broadening product offering + focus on premium strains), they should be able to partially offset the stagnating/slightly decrease sales in Germany, in our view.

Driving European expansion. Cantourage should be entering additional promising European markets such as Spain and Italy, which are gradually emerging markets following regulatory changes. In October of last year, Spain has officially integrated medicinal cannabis into its healthcare system under strict pharmaceutical rules, allowing only standardized THC/CBD extracts prescribed by specialists and dispensed through hospital pharmacies. While we don’t expect notable revenue contributions for FY26e, the company should define go-to-market strategies and realize first small sales volumes (eNuW).

Corporate governance improvements are imminent. As previously announced, Cantourage’s new CFO assumed office at the beginning of the year. Coupled with the extension of the CEO’s contract by five years and additional hires, the group took the necessary steps to significantly enhance leadership continuity, reinforce internal control structures, and improve the quality and timeliness of financial reporting, ultimately establishing a stronger governance platform to support future growth. The outstanding FY24 consolidated annual report is expected to be published shortly, eNuW.

We confirm our BUY rating with a € 10 PT based on a DCF.
 

You can download the research here: cantourage-group-se-2026-01-20-update-en-c4af5
For additional information visit our website: https://www.nuways-ag.com/research-feed

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2262540  20.01.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer